Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28449621 | 0.67 | ADORA3 (0.30) | ADORA3 | |
| SCHEMBL28540604 | 0.66 | — | — | |
| SCHEMBL23382050 | 0.65 | CYP2C19 (0.33) | ADORA3CYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL11857278 | 0.64 | — | — | |
| SCHEMBL18897783 | 0.64 | — | — | |
| SCHEMBL4954116 | 0.64 | — | — | |
| SCHEMBL18811618 | 0.64 | — | — | |
| SCHEMBL28985462 | 0.64 | USP2 (0.42) | ADORA3CYP2C19USP2ALDH1A1LMNA | |
| SCHEMBL18483088 | 0.64 | TSHR (0.38) | CYP2C19ALDH1A1TSHR | |
| Bicarbonate SCHEMBL14990798 | 0.63 | CYP2C19 (0.38) | ADORA3CYP2C19USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912617-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2003-04-16 | — | — | EP | claimed |
| US-6313238-B1 | POLYMERIZATION OF ALPHA-OLEFINS IN PRESENCE OF POLYMERIZATION CATALYST SYSTEM COMPRISING REACTION PRODUCT OF TITANIUM COMPOUND, AND ELECTRON DONOR COMPRISING MALONIC ESTER SUPPORTED ON MAGNESIUM HALIDE, ALKYLALUMINUM COMPOUND | BASELL TECHNOLOGY COMPANY BV (NL) | 2001-11-06 | — | — | US | claimed |
| US-6048818-A | Components and catalysts for the polymerization of olefins | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-04-11 | — | — | US | claimed |
| EP-0912617-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Montell Technology Company bv (NL) | 1999-05-06 | — | — | EP | claimed |
| WO-1998056833-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-12-17 | — | — | WO | claimed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-0912617-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6313238-B1 | POLYMERIZATION OF ALPHA-OLEFINS IN PRESENCE OF POLYMERIZATION CATALYST SYSTEM COMPRISING REACTION PRODUCT OF TITANIUM COMPOUND, AND ELECTRON DONOR COMPRISING MALONIC ESTER SUPPORTED ON MAGNESIUM HALIDE, ALKYLALUMINUM COMPOUND | BASELL TECHNOLOGY COMPANY BV (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6048818-A | Components and catalysts for the polymerization of olefins | MONTELL TECHNOLOGY COMPANY BV (NL) | 2000-04-11 | — | — | US | disclosed |
| EP-0912617-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Montell Technology Company bv (NL) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998056833-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | ADORA3 3342/4885CYP2C19 1827/4885USP2 516/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | ADORA3 3996/4885CYP2C19 4667/4885USP2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.